MK-3475-630/KEYNOTE-630

Name No. For Patients with Purpose
MK-3475-630/KEYNOTE-630 CTRIAL-IE 20-08

Melanoma

This is a randomized study that compares pembrolizumab with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy. The primary hypothesis is that pembrolizumab is superior to placebo in increasing recurrence free survival (RFS).


R2810-ONC-1788

Name No. For Patients with Purpose
R2810-ONC-1788 CTRIAL-IE 18-50

Melanoma.

This study will evaluate Adjuvant Cemiplimab Versus Placebo


BMS CA045-001

Name No. For Patients with Purpose
BMS CA045-001 CTRIAL-IE 18-51

Melanoma.

This study will evaluate the efficacy of NKTR-214 Combined with Nivolumab Versus Nivolumab


BMS CA209-8FC

Name No. For Patients with Purpose
BMS CA209-8FC CTRIAL-IE 19-13

Melanoma.

The study will compare the pharmacokinetics of BMSCHO1-Nivolumab Process D to Nivolumab Process C


CA045-001

Name No. For Patients with Purpose
CA045-001 18-51

Previously untreated or unresectable or Metastatic Melanoma

The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread.


R2810-ONC-1788

Name No. For Patients with Purpose
R2810-ONC-1788 18-50

Cutaneous Squamous Cell Carcinoma (High Risk)

The primary objective of the study is to compare disease-free survival (DFS) of patients with high-risk cutaneous squamous cell carcinoma (CSCC) treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and radiation therapy (RT).